24.03.2017 • News

Sherwin-Williams and Valspar Merger Delayed

Completion of the merger of US paint companies Sherwin-Williams and Valspar has been postponed from Mar. 21 to Jun. 21, 2107 because of delays related to the sale of one of Sherwin-William’s businesses that is required before regulators can clear the deal.

Sherwin-Williams has not identified the business it is trying to sell. However, the Cleveland,  Ohio-based group confirmed that the required divestment will not impact the price of $113 per share that it has agreed to pay. Under the original agreement, if regulators required Sherwin-Williams to sell assets totaling more than $650 million in annual revenues, the purchase price for Valspar would fall to $105 per share.

John Morikis, chairman, president and CEO of Sherwin-Williams, said the company is in discussions with a number of prospective buyers and it continues to move forward on the divestment of a single business that it believes would allow the Federal Trade Commission to grant approval. He commented: “We remain confident in our ability to complete the divestiture at a fair price and we look forward to unlocking the value of the combined business when the Valspar acquisition closes”.

Sherwin-Williams said the extension to June should provide enough time to complete both transactions. It expects to provide more definitive timing during its first-quarter earnings conference call scheduled for Apr. 20.

The Valspar deal is reported to be the largest acquisition in Sherwin-William’s 150-year history.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.